Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed measurable squamous cell carcinoma of the vulvar with an assessable lesion on the vulva or measurable metastatic disease. Tumors may be primary or recurrent. Patients must have plans for surgery or definitive treatment with chemotherapy +/-radiation unless they have measurable metastatic disease.~* 18 years of age or older~* No concurrent chemotherapy or radiotherapy~* NO previous chemotherapy or radiotherapy within the preceding 1 month~* ECOG performance status of 0-1~Exclusion Criteria:~* Known hypersensitivity reaction to erlotinib~* Other coexisting malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma~* Treatment with a non-FDA approved or investigational drug within 30 days~* Persistent toxicities (grade 2 or above) from previous treatment, expect alopecia or lymphedema~* Serum creatinine level greater than CTC grade 2~* Pregnancy or breast feeding~* Severe or uncontrolled systemic disease~* Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).